Drug Interactions between Dextrose 5% in Lactated Ringer's Injection and thiabendazole
This report displays the potential drug interactions for the following 2 drugs:
- Dextrose 5% in Lactated Ringer's Injection (lvp solution)
- thiabendazole
Interactions between your drugs
No interactions were found between Dextrose 5% in Lactated Ringer's Injection and thiabendazole. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Dextrose 5% in Lactated Ringer's Injection
A total of 0 drugs are known to interact with Dextrose 5% in Lactated Ringer's Injection.
- Dextrose 5% in lactated ringer's injection is in the drug class intravenous nutritional products.
- Dextrose 5% in lactated ringer's injection is used to treat Dehydration.
thiabendazole
A total of 52 drugs are known to interact with thiabendazole.
- Thiabendazole is in the drug class anthelmintics.
- Thiabendazole is used to treat the following conditions:
Drug and food interactions
thiabendazole food
Applies to: thiabendazole
MONITOR: Coadministration with thiabendazole may increase the plasma concentrations of caffeine. The mechanism is thiabendazole inhibition of the CYP450 1A2 metabolism of caffeine. In ten healthy, nonsmoking volunteers, administration of a single 136.5 mg dose of caffeine in combination with a single 500 mg dose of thiabendazole resulted in a nearly 60% increase in the area under the plasma concentration-time curve (AUC) of caffeine compared to administration without thiabendazole. In addition, the half-life of caffeine was increased from 11.9 to 28.6 hours, and oral clearance was reduced by 67% during coadministration with thiabendazole. The formation of paraxanthine from caffeine, which is primarily mediated by CYP450 1A2, was almost completely abolished until after the thiabendazole was cleared from the system.
MANAGEMENT: Patients should be advised that pharmacologic effects of caffeine may be increased during coadministration with thiabendazole.
References
- Bapiro TE, Sayi J, Hasler JA, et al. (2005) "Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans." Eur J Clin Pharmacol, 61, p. 755-61
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.